Core Insights - ADC Therapeutics is participating in two investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders [1] Group 1: Upcoming Conferences - ADC Therapeutics will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:50 a.m. EST, with CEO Ameet Mallik as the speaker [1] - The company will also participate in the Jefferies Biotech on the Beach Summit on March 11, 2026, focusing on one-on-one meetings [1] Group 2: Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients [1] - The company's CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [1] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [1]

Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate (ADC) designed to treat adult patients with relapsed or refractory large B-cell lymphoma [5][9]. - The FDA and EMA have approved ZYNLONTA for patients after two or more lines of systemic therapy, with the potential for peak revenue in the U.S. estimated between $600 million to $1 billion annually [3][7]. Company Background - ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates, focusing on innovative treatments through its portfolio, including ZYNLONTA [8][10].

Core Insights - ADC Therapeutics reported preliminary unaudited net product revenue of approximately $22 million for Q4 2025 and $73 million for the full year 2025, showing growth from $69.3 million in 2024 [1][3] - The company ended 2025 with cash and cash equivalents of approximately $261 million, providing a cash runway expected to last at least until 2028 [1][3] - Anticipated near-term catalysts include complete enrollment in the LOTIS-7 trial in the first half of 2026 and topline data from the LOTIS-5 Phase 3 trial in Q2 2026 [1][5] Financial Performance - ZYNLONTA net product revenue for 2025 is expected to be approximately $73 million, an increase from $69.3 million in 2024 [3] - Q4 2025 net product revenue is projected to be around $22 million, compared to $16.4 million in Q4 2024, reflecting variability in customer ordering [3] - The underlying demand for ZYNLONTA in the current 3L/3L+ DLBCL indication remained stable year-over-year [3] Clinical Developments - Updated data from the LOTIS-7 trial showed an 89.8% best overall response rate and a 77.6% complete response rate among 49 efficacy evaluable patients [4] - Enrollment in the LOTIS-7 trial is ongoing, with complete enrollment of approximately 100 patients expected in the first half of 2026 [4] - LOTIS-5 topline results are anticipated in Q2 2026, with full results expected by the end of 2026 [5] Regulatory and Strategic Outlook - Assuming positive results from ongoing trials, the company anticipates potential compendia inclusion for LOTIS-5 and LOTIS-7 in the first half of 2027, followed by regulatory approvals [2][5] - Investigator-initiated trials of ZYNLONTA in indolent lymphomas are ongoing, with promising initial data expected to be published by the end of 2026 [6] - The company has completed IND-enabling activities for a PSMA-targeting ADC and is exploring partnership opportunities [7][8]

Core Viewpoint - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will present at the J.P. Morgan Healthcare Conference on January 15, 2026 [1] Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, which includes ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5] Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4] - The company is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4]

Core Viewpoint - ADC Therapeutics SA has granted options to purchase 6,000 common shares to a new employee as an inducement for employment, aiming to motivate and reward high performance [1][2]. Group 1: Grant Details - The grant was approved by the Compensation Committee under the Company's Inducement Plan to encourage significant contributions to the Company's success [2]. - The options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the next three years, fully vesting by the fourth anniversary [3]. Group 2: Company Overview - ADC Therapeutics is a leader in antibody drug conjugates (ADCs), with a focus on transforming treatment for patients through its portfolio, including ZYNLONTA [4]. - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [5]. - The company is also developing a next-generation PSMA-targeting ADC with a differentiated payload and novel linker [5]. Group 3: Company Operations - ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, focusing on innovation in ADC development from clinical to commercialization [6].

Core Viewpoint - ADC Therapeutics is under investigation for potential securities fraud and unlawful business practices following a press release regarding clinical trial data that may have misrepresented adverse events [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics, focusing on whether the company and its officers engaged in securities fraud [1]. - The investigation is prompted by concerns over the company's recent disclosures and the implications for investors [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [2]. - The press release, while positive, noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [2]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial data, ADC's stock price fell by $0.65 per share, representing a 14.13% decline, closing at $3.95 per share on December 3, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Core Insights - ADC Therapeutics (NYSE:ADCT) is highlighted as a promising investment opportunity, particularly in the context of its lymphoma treatment developments [1][2] - Recent positive interim Phase Ib data from the LOTIS-7 trial has led to reaffirmed buy ratings from analysts, with price targets set at $10.00 by Guggenheim and $5.00 by RBC Capital [1][2] Trial Results - The LOTIS-7 trial demonstrated an overall response rate of 89.8% and a complete response rate of 77.6% among 49 efficacy-evaluable patients, indicating strong efficacy for ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma [3] - The trial results support the potential of ZYNLONTA and glofitamab as leading bispecific antibody-based combinations for patients with 2L+ DLBCL [3] Regulatory Approvals - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission as a treatment option for relapsed or refractory diffuse large B-cell lymphoma, enhancing its market position [5][6] Company Overview - ADC Therapeutics is a commercial-stage biotech company focused on developing targeted cancer therapies using Antibody-Drug Conjugates (ADCs) and proprietary Pyrrolobenzodiazepine (PBD) technology [6]

Group 1: Snowflake Inc - Snowflake Inc reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 following the earnings report [2] Group 2: Other Companies - Net Lease Office Properties saw a decline of 14.7%, with shares dropping to $25.19 in pre-market trading [4] - Symbotic Inc shares fell 10.5% to $65.50 after announcing a 10 million share offering [4] - Capricor Therapeutics Inc experienced an 8.4% dip to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA shares declined 8.1% to $3.63 following updated trial data [4] - Koninklijke Philips NV shares fell 6.8% to $26.11 in pre-market trading [4] - Omeros Corp declined 4.2% to $10.18, while Methanex Corp fell 3.8% to $35.95 [4]

Group 1: Snowflake Inc (NYSE:SNOW) - Snowflake reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 [2] Group 2: Other Companies - Net Lease Office Properties (NYSE:NLOP) shares decreased by 14.7% to $25.19 in pre-market trading [4] - Symbotic Inc (NASDAQ:SYM) shares dropped 10.5% to $65.50 following a 10 million share offering announcement [4] - Capricor Therapeutics Inc (NASDAQ:CAPR) shares fell 8.4% to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA (NYSE:ADCT) shares declined 8.1% to $3.63 after reporting updated data from its LOTIS-7 trial [4] - Koninklijke Philips NV (NYSE:PHG) shares decreased by 6.8% to $26.11 in pre-market trading [4] - Omeros Corp (NASDAQ:OMER) shares fell 4.2% to $10.18 [4] - Methanex Corp (NASDAQ:MEOH) shares dropped 3.8% to $35.95 [4]